WithdrawnPhase 2NCT05146882
An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)
Studying Alpha-1-antitrypsin deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- Principal Investigator
- Anne-Sophie Sejling, MDDicerna Pharmaceuticals
- Intervention
- Belcesiran(drug)
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2021 – 2022
Study locations (1)
- Auckland Clinical Studies, Grafton, Auckland, New Zealand
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05146882 on ClinicalTrials.govOther trials for Alpha-1-antitrypsin deficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07431112A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD)AIRNA Corporation
- RECRUITINGPHASE4NCT07135427Genetic Variation in IgG in Alpha 1 Antitrypsin DeficiencyUniversity of Alabama at Birmingham
- RECRUITINGNCT07152834Screening for Alpha-1 Antitrypsin Deficiency in Patients With Airway ObstructionMuğla Sıtkı Koçman University
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT07193615Study of YOLT-202 in the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)RenJi Hospital
- RECRUITINGNCT06505603PiMZ Longitudinal Cohort (PiMZ Logic)Columbia University
- RECRUITINGPHASE1NCT06996756Gene Therapy for Alpha 1- Antitrypsin DeficiencyWeill Medical College of Cornell University
- ACTIVE NOT RECRUITINGPHASE1NCT06738017Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult ParticipantsBioMarin Pharmaceutical
- ENROLLING BY INVITATIONNANCT06892236Preparation of IPSC for Cell Gene Editing for the Treatment of AATDFondazione IRCCS Policlinico San Matteo di Pavia